Johnson & Johnson 10-Q quarterly reports

Johnson & Johnson announced robust Q2 2026 financial results, with sales up 6.6% year-over-year, driven by strong performance in both Innovative Medicine and MedTech segments.

Johnson & Johnson reported a 9.9% increase in first-quarter sales to $24.1 billion, with the Innovative Medicine segment showing robust growth, partially offset by declines in Immunology.

Johnson & Johnson reported a 104% surge in net earnings for the fiscal nine months ended September 28, 2025, primarily driven by a $7 billion reversal of talc litigation reserves, alongside 5.0% total sales growth.

Johnson & Johnson's second quarter and first half 2025 financial results show significant net earnings growth, primarily due to the reversal of a substantial talc litigation reserve, alongside robust performance in Innovative Medicine and MedTech segments boosted by recent acquisitions.

Johnson & Johnson's Q1 2025 results reflect a significant reversal of talc reserves and the impact of strategic acquisitions, alongside operational growth in key segments.

Johnson & Johnson's Q3 2024 results show a mixed performance with revenue growth offset by significant charges related to talc litigation and strategic acquisitions.

Johnson & Johnson's second quarter results show a mix of revenue growth and increased expenses, including significant charges related to talc litigation and strategic acquisitions.

Johnson & Johnson's first quarter results for 2024 show a mixed performance with revenue growth offset by significant charges related to talc litigation and a decline in COVID-19 vaccine sales.